To the Editor The optimal timing of surgery following chemoradiotherapy for rectal cancer continues to be debated. Adding to the literature is a recent analysis of Italian registry data,1 finding that surgery beyond 8 weeks in patients with a poor response was associated with worse survival outcomes. Based on this finding, the authors recommend patients who do not respond well to chemoradiotherapy (ypT3-4 or N1-2) should “be identified early…and undergo surgery without delay.”1 We are concerned that this strong recommendation was drawn from a single uncontrolled data series. Further, this approach is practically limited by the timing and accuracy of standard chemoradiation response assessment.
Dunn C, Gately L, Gibbs P. Comment on Timing of Surgery For Patients With Rectal Cancers Not Responding to Preoperative Chemoradiation. JAMA Surg. 2022;157(6):548–549. doi:10.1001/jamasurg.2021.7590
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.